The engineering of novel properties and functions into viral vectors for improved gene delivery remains a barrier to the development of efficient, customized gene delivery vehicles. Rational methods for designing improved viral vectors are often experimentally challenging and laborious, particularly when knowledge of viral structure-function relationships is limited. As an alternative, high-throughput libraries may be rapidly and efficiently selected for viral variants with a desired function. Here we describe a transposon-based insertional mutagenesis approach to generate large diverse adenoassociated viral (AAV) libraries containing a randomly located peptide. Briefly, a selectable marker is randomly inserted throughout the AAV2 cap gene and the resulting "bookmarked" AAV cap gene is cloned into an AAV packaging vector. The selectable marker is then replaced with a defined oligonucleotide, and the final AAV library is used to package a diverse pool of AAV virions, which can used for functional selection.
Introduction
Adeno-associated viral (AAV) vectors show tremendous potential for the safe and effective treatment of a range of genetic disorders, including Alzheimer's disease, hemophilia, and Parkinson's disease (1,2). AAV is a non-pathogenic parvovirus with a 4.7-kb single-stranded DNA genome that contains two viral genes: rep and cap (3,4). While rep encodes four proteins (Rep78, Rep68,
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Edited by: J. M. Le Doux © Humana Press, Totowa, NJ Rep52, and Rep40) essential for viral replication, cap encodes three structural proteins (VP1-3) that self-assemble as a 60-mer to form the viral protein shell or capsid. The extensive safety record coupled with the high efficiency of AAV vectors has furthered their use to deliver genes to various dividing and nondividing cell types in vivo (5-7). While natural evolution has generated numerous alternatives to the well-characterized and most clinically utilized AAV serotype 2 (AAV2) (8,9), numerous remaining challenges, such as a robust universal purification platform and engineering cell-specific tropism, limit the gene delivery potential of these viral vectors. Genetic engineering has greatly extended our knowledge of AAV biology and enhanced its gene delivery properties. Site-directed mutagenesis studies have identified amino acids critical to AAV2 function (10-13), and the insertion of some peptides in defined positions in the AAV capsid, guided by sequence alignment with related parvoviruses (14,15) and crystal structures (12,16), has conferred recombinant AAV vectors with some cell-specific delivery properties. However, these rational design approaches can be laborious, and results are often highly variable, as evidenced by large differences in functional peptide display and viral infectivity for various peptides inserted into the same location (10,12). Alternative high-throughput library approaches have selected AAV vectors with novel cell-targeting peptides inserted at a defined capsid location (17,18), altered receptor binding properties (19), and the ability to evade antibody neutralization (19). However, the same insertion location is likely not optimal for displaying all functional peptide inserts, and directed evolution approaches do not typically involve the insertion of a peptide of defined function into a protein. Therefore, inserting known peptides or domains randomly throughout the entire primary amino acid sequence of the viral structural proteins may generate viral capsids with novel functions. Endonuclease methods have been used to engineer both bacterial and mammalian proteins (20,21), but such techniques fail to yield large diverse random libraries because of low DNA ligation efficiencies and biased insertions. Alternatively, transposases, enzymes capable of moving or copying DNA sequences randomly from one DNA template to another (see Fig. 1A ), have greatly facilitated prokaryotic and eukaryotic evolution through random DNA insertions into an organism's genome (22). Insertional mutagenesis using such transposases has improved functional genomics studies of viral genomes (23-25), and we have recently built on this approach to identify novel peptide insertion sites within the vesicular stomatitis virus protein for retroviral and lentiviral vector engineering (26).
Transposon insertional mutagenesis relies on the transposase-facilitated transfer of a unique drug-resistance gene from a donor plasmid to a random location in an acceptor plasmid, containing the gene of interest, followed by subsequent selection with the appropriate antibiotics. Subsequent replacement of the drug-resistance gene with an oligonucleotide encoding a desired peptide results in a diverse plasmid library, which can be used to produce virus containing the peptide randomly located within the viral capsid. Here we present a detailed protocol for employing a transposon-based system to randomly insert an oligonucleotide encoding for a peptide of interest [i.e., a hexahistidine (His 6 ) tag] throughout the entire AAV2 cap gene. Other motifs to modulate cell surface binding or other viral properties can also be inserted. Therefore, this general protocol is readily extended to other peptides, AAV serotypes, and viruses to generate customized viral gene delivery vectors.
Materials

2.5 M calcium chloride (CaCl 2 ).
2. 2× HeBS: 1.5 mM Na 2 HPO 4 , 50 mM HEPES, 280 mM NaCl, pH 7.10. 3. AAV lysis buffer: 50 mM Tris-HCl, 150 mM NaCl, pH 8.5.
Methods
Construction of AAV cap Plasmid
1. To obtain AAV cap gene from viral genomic DNA or plasmid, mix in a PCR tube: 5 μl 10× Thermopol buffer, 5 μl dimethyl sulfoxide (DMSO), 1 μl 10 mM dNTP mix, ∼0.1 pmol DNA template, 10 pmol of 5´and 3´primers containing suitable restriction sites for cloning, 5 U Vent DNA polymerase, and water to 50 μl. For example, to recover the AAV2 cap gene, use 5´-GCGGAAGCTTCGATCAACTACGC-3´as the 5´primer and 5´-GGGGCGCGCCGCAATTACAGATTACGAGTCAGGTATCTGGTG-3´as the 3´primer. These primers introduce HindIII and AscI restriction sites (in bold), respectively, to facilitate cloning. 2. Using a QIAquick purification kit or similar spin column kit, purify the polymerase chain reaction (PCR). 3. The construction of a small plasmid vector (e.g., pBluescript) containing only the AAV cap gene ensures that more insertion events occur in the cap gene versus the vector backbone and thus reduces the final required library size, which should be significantly larger than the total number of base pairs in the template plasmid to ensure every possible position is well represented. However, the unique NotI site within pBluescript must first be eliminated because the transposon reaction introduces a NotI site. This may be accomplished by either mutagenesis or insertion of a small oligonucleotide linker at the NotI site to introduce a unique AscI site (see Note 1). 4. Digest ∼1 μg both the 2.6-kb AAV cap PCR product and modified pBluescript plasmid with HindIII and AscI. Purify the digested products using a ∼1% agarose gel and a commercial gel extraction kit, such as Qiagen QIAEX II Gel Extraction Kit. 5. Ligate 75-150 fmol of AAV cap PCR product and 25 fmol of pBluescript with 5 U of T4 DNA ligase in a 15 μl reaction. 6. Transform 10 μl of ligation into TOP10 bacteria and select for growth in the presence of ampicillin (100 μg/ml). 7. To screen for positive clones, digest plasmid DNA with HindIII and AscI. Positive clones will yield two bands: 2.6 and 3.0 kb. Fig. 1 and Note 4). 4. Purify the DNA mixture by ethanol precipitation through addition of 2 μl 3M NaOAc, pH 5.2, and 50 μl 100% ethanol. We recommend adding glycogen (100 μg/ml final concentration) carrier as a pellet marker. Thoroughly wash the pellet with 70% ethanol and air dry. Resuspend the dried pellet in no more than 10 μl water. 5. Transform the purified ligation reaction into ElectroMAX DH10B bacteria through electroporation according to the manufacturer's instructions. Take a small fraction of the electroporation reaction and streak on a bacterial agar plate with ampicillin and chloroamphenicol. Estimate the initial plasmid diversity of the library from the number of bacterial colonies. Typical initial library diversity should be on the order of 10 6 independent bacterial clones. 6. Inoculate a 100 ml TB culture with the remaining reaction and shake culture at 250 rpm (1.3 × g) for 13 h at 37ºC in the presence of 100 μg/ml ampicillin and 10 μg/ml chloroamphenicol. 7. Purify DNA from culture using a standard DNA purification method such as polyethylene glycol (PEG) precipitation or a commercial purification kit. Quantify purified DNA by measuring the absorbance at 260 nm using a UV-Vis spectrophotometer. A diagnostic restriction digest screen with EagI (which cuts once in the oligo insert and once at end of the cap gene) should yield a smear ranging from 20 bp to 2.6 kb in size (see Fig. 2 ).
Transposon-Based Insertion
Construction of AAV Plasmid Library
Production of Viral Library
1. Plate ∼10 7 HEK 293 cells in 25 ml of DMEM onto a 15-cm tissue culture dish such that cells are ∼75% confluent after 24 h. 2. After ∼24 h, transfect cells by calcium phosphate precipitation (19). Briefly, mix 7 ng pSub2Asc library, 25 μg pBluescript, and 25 μg pHelper with 120 μl 2.5 Fig. 2 . Analysis of plasmid library diversity. The His 6 AAV insertion library and single clones contain two EagI sites, one that cuts once in the His 6 insertion and one at 3´end of the AAV cap gene. Successful insertions into cap will yield a large band ranging from 8.3 to 5.7 kb, along with a smaller band ranging up to 2.6-kb in size (indicated by arrow). Lanes: 1, 1-kb ladder; 2, His 6 AAV library; 3-12, 10 randomly selected single His 6 AAV clones; 13 1-kb ladder.
M CaCl 2 and water to 2.5 ml total volume. The pBluescript helps to maintain a constant DNA : calcium phosphate ratio, which we have found necessary for maintaining high efficiency DNA transfection and viral packaging. Add DNA/CaCl 2 solution dropwise to 2× HeBS solution. Mix once and add mixture dropwise to cells. Remove media after 6-8 h and replace with 25 ml DMEM. This 1:2 × 10 −4 molar ratio of plasmid DNA to pSub2Asc library was calculated such that >90% of cells received approximately one member of pSub2Asc library, assuming each cell receives ∼50,000 total plasmids (27). This helps to ensure that most virions contain a viral genome with a cap gene encoding their capsid (see Note 7). 3. After 48 h, scrape cells from the plate and centrifuge at 1000 × g for 2 min.
Aspirate medium and resuspend cell pellet in 1 ml PBS or AAV lysis buffer (50 mM Tris, 150 mM NaCl, pH 8.5). 4. Freeze/thaw three times using a dry ice/ethanol bath, or sonicate the cell suspension, to lyse the cells. Ni-NTA agarose (Qiagen, Valencia, CA, USA) was agitated gently overnight at 4°C. This slurry was then loaded onto a plastic column (Kontes, Vineland, NJ, USA) before washing with 3 ml of wash buffer (10 mM Tris-HCl pH 8.0, 50 mM imidazole) and eluting with 3 ml of elution buffer (10 mM Tris-HCl pH 8.0, 500 mM imidazole). Characterization of the binding profile of the viral library showed elevated levels of Ni-NTA binding relative to the wild type AAV2 control (see Fig. 3B ). verify the transfer of the drug-resistance gene. 5. The ratio of the amount of the plasmid insert to plasmid backbone may be varied to identify the optimal cloning condition. 6. Alternate oligonucleotides or gene fragments may be used provided the ends contain restriction sites compatible with NotI overhangs. Alternatively, the NotI overhangs may be blunted or filled in with Klenow, and the oligonucleotides may be cloned into the modified site. 7. Alternative transfection methods such as electroporation or lipofection may be used. In all cases, high transfection efficiency and proper plasmid amounts are essential for producing a diverse viral library that can be easily functionally selected. 8. For selection protocols involving infection of a cell line, such as HEK293 (19), care should be taken to avoid infection with a large (>1000) number of virions per cell [i.e., multiplicity of infection (MOI)]. The presence of multiple AAV genomes with different cap genes in one cell leads to potential recombination between the cap genes or production of several different versions of the VP1-3 proteins, yielding chimeric or mosaic virions (28,29). Hence, isolation of the genomes from these mosaic virions will fail to recover the genotype responsible for the novel property or phenotype.
Notes
